Deal Watch: Auxilium Joins The Tax-Inversion Wave As BIO Keeps The Deal Tide High

Endo expanded its generics business by purchasing Dava, EMD Serono partnered with Mersana on antibody-drug conjugates and Ligand in-licensed a cancer and autoimmune disease candidate from TG Therapeutics. It was all part of a hectic deal-making week coinciding with the annual BIO conference in San Diego.

The Biotechnology Industry Organization annual conference, held in San Diego June 23-26, always produces a flurry of activity for industry business development pros – by Deal Watch’s count there were about two dozen biopharma deals during the week. Highlights from the sun and fun are among the summaries of themost noteworthy transactions that occurred between June 21 and June 28.

BIO Highlights From “The Pink Sheet” DAILY

More from Archive

More from Pink Sheet